A systematic review of clozapine induced cardiomyopathy

International Journal of Cardiology

Volumn 176, Issue 2, 2014, Pages 315-320

  Alawami, Mohammed ^a   Wasywich, Cara ^a   Cicovic, Aleksandar ^a   Kenedi, Christopher ^a  

^a AUCKLAND DISTRICT HEALTH BOARD   (New Zealand)

Author keywords

Cardiomyopathy; Clozapine; Echocardiography; Systematic review

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CLOZAPINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; HALOPERIDOL; INOTROPIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; STEROID; WARFARIN;

AGRANULOCYTOSIS; ARTICLE; CARDIOMYOPATHY; COMORBIDITY; CONGESTIVE CARDIOMYOPATHY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG RECHALLENGE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; FATIGUE; FOOT EDEMA; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PALPITATION; HUMAN; LUPUS ERYTHEMATOSUS; MORTALITY; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; PERICARDITIS; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT DURATION; ANIMAL; CASE REPORT; CHEMICALLY INDUCED; ECHOGRAPHY;

ANIMALS; ANTIPSYCHOTIC AGENTS; CARDIOMYOPATHIES; CLOZAPINE; HUMANS;

EID: 84922407443     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.07.103     Document Type: Review

References (53)

1. Voruganti L, Cortese L, Oyewumi L, et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, sideeffect profile and impact on quality of life. Schizophr Res 2000; 43: 135-45.
2. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatmentresistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-96.
3. Kane JM. Treatment-resistant schizophrenic patients. J Clin Psychiatry 1996; 57(Suppl. 9): 35-40.
4. Lewis SW, Barnes TRE, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsy-chotic drugs in resistant schizophrenia. Schizophr Bull 2006; 32: 715-23.
5. Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: A meta-analysis. Schizophr Res 2005; 73: 139-45.
6. Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology 1997; 8: 671-7.
7. Conley RR. Optimizing treatmentwith clozapine. J Clin Psychiatry 1998; 59(Suppl. 3): 44-8.
8. Krakowski MI, et al. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry Jun 2006; 63: 622-9.
9. Wheeler A, Hymerstone V, Robinson G. Outcomes for schizophrenia patients with clozapine treatment: How good does it get? J Psychopharmacol Nov 2009; 23(8): 957-65.
10. Tiihonen J, et al. 11-Year follow-up of mortality in patients with schizophrenia: A population-based cohort study (FIN11 study). Lancet Jul 2009; 11.
11. Wheeler A. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. Ann Pharmacother June 2008; 42.
12. Libbus Y, Gardner D, Milliken H. Utilization of Clozapine in Nova Scotia 1990-2004. Canadian Psychiatric Association 56th Annual Conference. Toronto: Canada: Canadian Psychiatric Association; 2006.
13. Leo RJ, Kreeger JL, Kim KY. Cardiomyopathy associated with clozapine. Ann Pharmacother June 1, 1996; 30(no. 6): 603-5.
14. Fontana PG, Sümegi B. Association of Clozaril (clozapine) with cardiovascular toxicity. 385 Bouchard Boulevard, Dorval, Quebec: Novartis Pharmaceuticals Canada Inc.; January 14 2002.
15. Bobb VT, et al. Adolescent with treatment-refractory schizophrenia and clozapine induced cardiomyopathy managed with high dose olanzapine. J Child Adolesc Psychopharmacol December 2010; 20(6): 539-43.
16. Reinders J, ParsonageW, Lange D, et al. Clozapine-relatedmyocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust N Z J Psychiatry Nov-Dec 2004; 38(11-12): 915-22.
17. Hoehns JD, Fouts MM, Kelly MW, et al. Sudden cardiac death with clozapine and sertraline combination. Ann Pharmacother Jul-Aug 2001; 35(7-8): 862-6.
18. Kropp S, Tountopoulou A, Schneider U, Lichtinghagen R. N-terminal fragment of B-type natriuretic peptide (NT-proBNP), a marker of cardiac safety during antipsychotic treatment. Ann Gen Psychiatry 2005; 4: 10-5.
19. La Grenade L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med Jul 19 2001; 345(3): 224-5.
20. Rostagno C, Domenichetti S, Gensini GF. Does a subclinical cardiotoxic effect of clozapine exist? Results from a follow-up pilot study. Cardiovasc Hematol Agents Med Chem 2012 Jun; 10(2): 148-53.
21. Khokhar W, Rele K, Birkett P. Clozapine related cardiomyopathy. J Psychiatr Intensive Care 2007 June; 3(1): 55-5722.
22. MurchS, TranN, LiewD, PetrakisM, PriorD, CastleD. Echocardiographicmonitoring for clozapine cardiac toxicity: Lessons from real-world experience. Australas Psychiatry 2013 Jun; 21(3): 258-61.
23. Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet Nov 27 1999; 354(9193): 1841-5.
24. Friman G,Wesslen L, Fohlman J, Karjalainen J, Rolf C. The epidemiology of infectious myocarditis, lymphocytic myocarditis and dilated cardiomyopathy. Eur Heart J 1995; 16(Suppl. O): 36-41.
25. Committee on Safety of Medicines. Myocarditis with antipsychotics: Recent cases with clozapine (Clozaril). Curr Probl Pharmacov 1993; 19: 9-10.
26. Montastruc G, Favreliere S, Sommet A, et al. Drugs and dilated cardiomyopathies: A case/noncase study in the French PharmacoVigilance Database. Br J Clin Pharmacol March 2010; 69(3): 287-94.
27. Phan KL, Taylor SF. Clozapine-associated cardiomyopathy. Psychosomatics May-Jun 2002; 43(3): 248.
28. Meltzer HY, Alphs L, Green AI, et al. International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry Jan 2003; 60(1): 82-91.
29. New Zealand Medicines and Medical Devices Safety Authority. Clozapine and achy breaky hearts. Prescr Update 2008; 29(1): 10-2.
30. Merrill DB, Dec W, Goff D. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol 2005; 25: 32-41.
31. Wehmeier P, Heiser P, Remschimidt H.Myocarditis, pericarditis and cardiomyopathy in patients treated with clozapine. J Clin Pharm Ther 2005; 30: 91-6.
32. Vaddadi K, Soosai E, Vaddadi G. Low blood selenium concentrations in schizophrenic patients on clozapine. Br J Clin Pharmacol 2003; 55: 307-9.
33. Yost BL, Gleich GJ, Fryer AD. Ozone-induced hyperresponsiveness and blockade of M2 muscarinic receptors by eosinophil major basic protein. J Appl Physiol 1999; 87: 1272-8.
34. Koren W, Kreis Y, Duchowiczny K, et al. Lactic acidosis and fatal myocardial failure due to clozapine. Ann Pharmacother 1997; 31: 168-170.46.
35. Agelink MW, Majewski T, Wurthmann C, et al. Effects of newer atypical antipsychotics on autonomic neurocardiac function. A comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol 2001; 21: 8-13.
36. Personal communication with Andrew Muir, Auckland University.
37. Manu P, Sarpal D, Muir O, et al. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res February 2012; 134(2-3): 180-6.
38. Floreani J, Bastiampillai T. Successful re-challenge with clozapine following development of clozapine-induced cardiomyopathy. Aust N Z J Psychiatry 2008 Aug; 42(8): 747-8.
39. Roh S, Ahn DH, Nam JH, et al. Cardiomyopathy associated with clozapine. Exp Clin Psychopharmacol 2006 Feb; 14(1): 94-8.
40. Current problems in pharmacovigilance 2002; 28: 8 with permission from the Medicines Control Agency, London, United Kingdom. Medsafe New Zealand 2003. http://www.medsafe.govt.nz/profs/PUarticles/clozcardiac.htm.
41. Nielsen J, Correll CU, Manu P, Kane JM. Termination of clozapine treatment due to medical reasons: When is it warranted and how can it be avoided? J Clin Psychiatry Jun 2013; 74(6): 603-13.
42. Rostagno C, Domenichetti S, Pastorelli F, Gensini GF. Clozapine associated cardiomyopathy: A cluster of 3 cases. Intern Emerg Med Jun 2011; 6(3): 281-3.
43. Remington G, Agid O, Foussias G, et al. Clozapine's role in the treatment of firstepisode schizophrenia. Am J Psychiatry Feb 1 2013; 170(2): 146-51.
44. De Knijff DW, Schepers PH, Blanken-Meijs JT. Cardiomyopathy during clozapine therapy. Ned Tijdschr Geneeskd Sep 1 2001; 145(35): 1697-9.
45. Tanner MA, CullingW. Clozapine associated dilated cardiomyopathy. Postgrad Med J Jul 2003; 79(933): 412-3.
46. Sagar R, Neeraj B, Sadhu R, et al. Clozapine-induced cardiomyopathy presenting as panic attacks. J Psychiatry Pract May 2008; 14(3): 182-5.
47. Charles A, et al. Masked clozapine induced cardiomyopathy. J Am Board Fam Med Jan-Feb 2008; 21(1): 70-4.
48. Povlsen UJ, Noring U, Fog R, Gerlach J. Tolerability and therapeutic effect of clozapine: A retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 1985; 71: 176-85.
49. Taneja AK, Wong J, Bayliss J. Antipsychotic-drug-induced dilated cardiomyopathy. BMJ Case Rep 2009. http://dx.doi.org/10.1136/bcr.09.2008.0958.
50. Kikuchi Y, Ataka K, Yagisawa K, et al. Clozapine-induced cardiomyopathy: A first case in Japan. Schizophr Res Nov 2013; 150(2-3): 586-7.
51. medsafe. http://www.medsafe.govt.nz/profs/PUarticles/clozcardiac.htm.
52. Kidd S, Chopra P, Stone J, et al. Monitoring of long-term cardiac complications in patients receiving clozapine. Australas Psychiatry Feb 2013; 21(1): 77-8.
53. Domenichetti S, Rostango C, Pastorelli F, Gensini G. Clozapine and cardiomyopathy. An investigation conducted in a MentalHealth Service. Giorn Ital Psicopat 2010; 16: 286-98.